HUTCHMED (China) Limited - ADR
HCM
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.33B
Close$
$18.74
39% upside
Current Fair Value
39% upsideUndervalued by 39% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.33 Billion |
|---|---|
| Enterprise Value | $2.32 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.65 |
| Beta | 0.43 |
| Outstanding Shares | 173,168,080 |
Return
| Return on Equity | 1.42% |
|---|---|
| Return on Assets | 1.03% |
| Return on Invested Capital | -2.38% |
Valuation & Multiples
| P/E Ratio | 149.75 |
|---|---|
| PEG | -155.18 |
| Price to Sales | 4.49 |
| Price to Book Ratio | 1.93 |
| Enterprise Value to Revenue | 4.23 |
| Enterprise Value to EBIT | -66.78 |
| Enterprise Value to Net Income | 129 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 3, 2026
EPS Estimate
$0.15
Average shareholder expectationRevenue Estimate
$306.40 M
Average shareholder expectationNext Earnings Call
Expected Date
March 4, 2027
EPS Estimate
$0.21
Average shareholder expectationRevenue Estimate
$329.08 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 2.50%▲ 0.03% |
|---|---|
| Total Invested | $46.55M▼ 27.22% |
| Investors Holding | 56▲ 3.00% |
ESG Score
No data
About Hutchison China Meditech Ltd.
1,796 employees
CEO: Christian Hogg HUTCHMED (China) Limited, a biopharmaceutical company established in 2000 and headquartered in Central, Hong Kong, focuses on the discovery, development, and commercialization of innovative targeted therapies and immunotherapies. The com...